Skip to main content

Table 4 Study period utilization and costs for patients with non-infectious uveitis by treatment group

From: Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA

 

CTS patients a

(N = 4,568)

IMS patients b

(N = 5,466)

BIO patients

(N = 1,694)

Total monthly healthcare resource utilization per patient, mean (SD)

 

  Inpatient stay (IP)

   

  Number of stays/patient

0.044 (0.34)

0.048 (0.30)

0.024 (0.19)a,b

  Number of days/ hospitalized patient

3.678 (3.89)

3.621 (4.18)

3.862 (3.68) b

  Emergency room (ER)

   

  Number of visits/patient

0.030 (0.13)

0.030 (0.13)

0.030 (0.13)a,b

  Office/outpatient (OP)

   

  Number of visits/patient

2.025 (1.81)

2.365 (1.95)

1.939 (1.55)

  Pharmacy services

   

  Number of scripts/patient

3.015 (2.36)

4.106 (2.93)a

3.389 (2.66)a,b

Total monthly healthcare costs per patient, mean [median] (SD) (US$)

1,144 [382] (3,601)

1,759 [484] (5,474)a

2,689 [2,194] (2,912)a,b

  Medical services (excluding study drugs)

902 [195] (3,445)

1,324 [196] (5,194)

716 [273] (2,005)a,b

  Inpatient stay (IP)

307 [0] (2,497)

436 [0] (3,891)

183 [0] (1,444)a,b

  Emergency room (ER)

21 [0] (148)

25 [0] (277)a

21 [0] (373)a,b

  Office/outpatient (OP)

574 [185] (1,720)

863 [186] (2,482)

512 [252] (1,110)a,b

  Pharmacy services (excluding study drugs)

227 [82] (576)

268 [85] (538)

201 [87] (398)

  Total study drug costs

16 [7] (26)

167 [64] (380)a

1,772 [1,491] (1,532)a,b

  Total costs excluding study drug costs

1,129 [365] (3,599)

1,592 [379] (5,383)

918 [466] (2,105)a,b

  1. CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were used to test differences in continuous variables. Healthcare costs and visits were calculated per-member-per-month (PMPM). Sample means and standard deviations were weighted by treatment months.a,bData with superscripted letter(s) indicates a significant difference (P < 0.05) from the uveitis subtype represented by that letter.